Sanders TDI's First Graduated Molecule Completes Phase 1

Sparian Biosciences Announces Results from the Phase 1 Clinical Trial of First in Class Novel Arylepoxamide Receptor (AEAr) Agonist Analgesic.   SBS-1000 was shown to be safe and well tolerated in healthy volunteers in this Phase 1 Single Ascending Dose (SAD) study no serious adverse events observed.

SBS-1000 was the first small molecule that emerged from the Sanders TDI portfolio in 2016. Sanders TDI applauds Dr. Jeff Reich and the team at Sparian Biosciences for their diligence and care in advancing this molecule for the benefit of patients with severe pain.